{"nctId":"NCT04466618","briefTitle":"Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes","startDateStruct":{"date":"2021-04-15","type":"ACTUAL"},"conditions":["Healthy","Type 2 Diabetes"],"count":23,"armGroups":[{"label":"Saline","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Saline"]},{"label":"Exendin-9,39","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Exendin-9,39"]},{"label":"Saline + Intralipid/Heparin","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Saline + Intralipid/Heparin"]},{"label":"Exendin-9,39 + Intralipid/Heparin","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Exendin-9,39 + Intralipid/Heparin"]}],"interventions":[{"name":"Saline","otherNames":[]},{"name":"Exendin-9,39","otherNames":[]},{"name":"Saline + Intralipid/Heparin","otherNames":[]},{"name":"Exendin-9,39 + Intralipid/Heparin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria - non-diabetic subjects:\n\n* Weight-stable, non-diabetic subjects\n\nExclusion Criteria - non-diabetic subjects:\n\n* Age \\< 25 or \\> 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).\n* HbA1c â‰¥ 6.5%\n* Use of glucose-lowering agents.\n* For female subjects: positive pregnancy test at the time of enrollment or study\n* History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.\n* Active systemic illness or malignancy.\n* Symptomatic macrovascular or microvascular disease.\n\nInclusion criteria - diabetic subjects:\n\n* Weight-stable, diabetic subjects treated with diet and lifestyle alone or with metformin monotherapy\n\nExclusion Criteria - diabetic subjects:\n\n* Age \\< 25 or \\> 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).\n* Use of any glucose-lowering agent other than metformin.\n* 2 or more fasting glucose values \\> 250mg/dl on medication or after medication withdrawal.\n* Unwillingness or inability to withdraw medication for three weeks prior to, and for the duration of the study.\n* For female subjects: positive pregnancy test at the time of enrollment or study\n* History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.\n* Active systemic illness or malignancy.\n* Symptomatic macrovascular or microvascular disease.","healthyVolunteers":true,"sex":"ALL","minimumAge":"25 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39","description":"Concentrations of glucagon Measured by immunoassay over the -30 to 0 minutes of study.\n\nOn one study day subjects received saline, on the other exendin-9,39. The infusion commenced at -120 minutes.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"1.2"},{"groupId":"OG001","value":"7.9","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"1.1"},{"groupId":"OG001","value":"10.2","spread":"0.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Hyperglycemia","IV access loss"]}}}